NASDAQ:GNPX Genprex Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.38 -0.01 (-0.72%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$1.36▼$1.4050-Day Range$1.28▼$1.6752-Week Range$1.17▼$3.62Volume1,726 shsAverage Volume98,200 shsMarket Capitalization$66.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Genprex MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.82% of Shares Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment1.27Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.42) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.28 out of 5 starsMedical Sector1054th out of 1,428 stocksPharmaceutical Preparations Industry516th out of 680 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genprex. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.82% of the outstanding shares of Genprex have been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Genprex has recently decreased by 9.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGenprex has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Genprex is -0.92. Previous Next 4.0 News and Social Media Coverage News SentimentGenprex has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genprex this week, compared to 1 article on an average week.Search Interest6 people have searched for GNPX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Genprex to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by Insiders10.58% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.66% of the stock of Genprex is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genprex are expected to decrease in the coming year, from ($0.42) to ($0.48) per share.Price to Book Value per Share RatioGenprex has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Email Address About Genprex (NASDAQ:GNPX) StockGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Read More GNPX Stock News HeadlinesJune 29, 2022 | americanbankingnews.comGenprex (NASDAQ:GNPX) Shares Up 3.6%June 2, 2022 | proactiveinvestors.comNA Proactive news snapshot: Information Services Corporation, Benchmark Metals, CULT Food Science, Benchmark Metals, AMPD Ventures ... - Proactive Investors USAJune 2, 2022 | finance.yahoo.comGenprex to Present at Upcoming June Investor Conferences - Yahoo FinanceJune 2, 2022 | finance.yahoo.comGenprex to Present at Upcoming June Investor ConferencesMay 19, 2022 | finance.yahoo.comGenprex to Present at Upcoming Investor Conference in May 2022 - Yahoo FinanceMay 19, 2022 | finance.yahoo.comGenprex to Present at Upcoming Investor Conference in May 2022May 17, 2022 | finance.yahoo.comHere's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn SituationMay 16, 2022 | globenewswire.comExtensive Stage Small Cell Lung Cancer Pipeline Review | Clinical Trial Analysis by DelveInsight - GlobeNewswireMay 7, 2022 | globenewswire.comProactive headlines including Twitter, Elon Musk, Japan Gold, Endeavour Mining, Kainantu Resources, Empower Clinics, AMPD Ventures and Information Services - GlobeNewswireMay 6, 2022 | finance.yahoo.comGenprex Issues Shareholder Letter and Provides 2022 Corporate Update - Yahoo FinanceMay 5, 2022 | proactiveinvestors.comUS stocks close in the red as recession fears grow following Fed"s interest rate hike - Proactive Investors USAMay 5, 2022 | proactiveinvestors.comUS stocks continue to tumble at noon amid recession fears, disappointing ecommerce earnings - Proactive Investors USAMay 5, 2022 | finance.yahoo.comProactive headlines including Twitter, Elon Musk, Japan Gold, Endeavour Mining, Kainantu Resources, Empower Clinics, AMPD Ventures and Information Services - Yahoo FinanceMay 5, 2022 | finance.yahoo.comGenprex Issues Shareholder Letter and Provides 2022 Corporate UpdateApril 18, 2022 | proactiveinvestors.comNA Proactive news snapshot: Helix BioPharma, ION Energy, Jushi Holdings, enCore Energy, Irwin Naturals, Gratomic UPDATE... - Proactive Investors USAApril 18, 2022 | finance.yahoo.comGenprex to Participate in Upcoming Investor and Industry Conferences in April 2022 - Yahoo FinanceApril 9, 2022 | finance.yahoo.comGenprex, Inc. (GNPX)April 2, 2022 | proactiveinvestors.comGenprex announces opening of patient enrollment for its Acclaim-2 clinical trial - Proactive Investors USAMarch 31, 2022 | globenewswire.comProactive news headlines including Disney, NEO Battery Materials, Delta 9 Cannabis, Dalrada Energy Services, ESE Entertainment, FansUnite Entertainment, Ximen Mining and Bridgeline Digital - GlobeNewswireMarch 31, 2022 | businesswire.comGenprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer - Business WireMarch 31, 2022 | finance.yahoo.comGenprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer - Yahoo FinanceMarch 23, 2022 | streetinsider.comInvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference - StreetInsider.comMarch 23, 2022 | finance.yahoo.comGenprex to Participate in Upcoming Investor Conference in March - Yahoo FinanceMarch 3, 2022 | streetinsider.comInvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial - StreetInsider.comMarch 3, 2022 | marketwatch.comGenprex Doses First Patient in Trial for Lung-Cancer Treatment - MarketWatchSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNPX CUSIPN/A CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees12Year FoundedN/ACompany Calendar Last Earnings5/13/2022Today7/05/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.00% Return on Assets-42.47% Debt Debt-to-Equity RatioN/A Current Ratio14.97 Quick Ratio14.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book1.60Miscellaneous Outstanding Shares47,900,000Free Float42,830,000Market Cap$66.10 million OptionableNot Optionable Beta-0.39 Genprex Frequently Asked Questions How has Genprex's stock price performed in 2022? Genprex's stock was trading at $1.31 at the start of the year. Since then, GNPX stock has increased by 5.3% and is now trading at $1.38. View the best growth stocks for 2022 here. When is Genprex's next earnings date? Genprex is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Genprex. How were Genprex's earnings last quarter? Genprex, Inc. (NASDAQ:GNPX) announced its earnings results on Friday, May, 13th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. View Genprex's earnings history. Who are Genprex's key executives? Genprex's management team includes the following people: Mr. John Rodney Varner, Co-Founder, Chairman, Pres & CEO (Age 65, Pay $747.18k)Mr. Ryan M. Confer M.S., Chief Financial Officer (Age 40, Pay $522.67k)Ms. Catherine M. Vaczy Esq., Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer (Age 61, Pay $597.58k)Dr. Hemant Kumar C.P.M., EMBA, Ph.D., Chief Manufacturing & Technology Officer (Age 59)Ms. Kalyn Dabbs, Sr. Mang. of Communications & MarketingMr. David M. Schloss, Sr. VP of HRMr. Thomas C. Gallagher Esq., Sr. VP of Intellectual Property & LicensingDr. William E. Gannon Jr., Member of Clinical Advisory Board & VP of Regulatory AffairsDr. Mark S. Berger M.D., Chief Medical Officer (Age 67)Mr. Greg Jancarik C.M.A., CPA, M.B.A., Corp. Controller Who are some of Genprex's key competitors? Some companies that are related to Genprex include Alpine Immune Sciences (ALPN), Verona Pharma (VRNA), Prelude Therapeutics (PRLD), InterCure (INCR), Thorne HealthTech (THRN), LianBio (LIAN), Sernova (SEOVF), Epizyme (EPZM), KalVista Pharmaceuticals (KALV), Rallybio (RLYB), PepGen (PEPG), XOMA (XOMA), Inventiva (IVA), CymaBay Therapeutics (CBAY) and AVEO Pharmaceuticals (AVEO). View all of GNPX's competitors. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD). What is Genprex's stock symbol? Genprex trades on the NASDAQ under the ticker symbol "GNPX." How do I buy shares of Genprex? Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genprex's stock price today? One share of GNPX stock can currently be purchased for approximately $1.38. How much money does Genprex make? Genprex (NASDAQ:GNPX) has a market capitalization of $66.10 million. How many employees does Genprex have? Genprex employs 12 workers across the globe. How can I contact Genprex? Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The official website for Genprex is www.genprex.com. The company can be reached via phone at (877) 774-4679 or via email at investors@genprex.com. This page (NASDAQ:GNPX) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
